Riding the sympathy train 🚂

Penny stocks gone wild                                                                                                                                                                                                                                                                                                                                                                                                                 October 12, 2023 *Together with MAIA Biotechnology (NYSE: MAIA) Good day, 360! Here are our top investing ideas today. These setups look primed! Be the best prepared trader on the Street! SECO - Up over 400% in sympathy with TPST OPGN - Up over 700% after receiving $750,000 euros from sale Unyvero A50 systems JAGX - Up over 50% in sympathy with OPGN *A Message on Behalf of MAIA Biotechnology  🔥 Hot Stock of the Day 🔥 This market continues to defy the naysayers. For those that have been listening to our outlook that the market made a significant bottom last week – you have done exceptionally well this week! For example, if you look at the stock idea we gave you on Tuesday, you’ll notice that it is around 30% higher now. Maybe we’re just “lucky” with the ideas we present to you, but we have found another idea we also think could be “lucky” as well. Our favorite technical indicator just fired off a few days ago on a small biotech stock: MAIA Biotech (MAIA). With the direction of this market and the incredible strength in MAIA, this one just looks too good to pass up right now. Just look at this chart to see what we mean… And insiders know what is brewing here too. The activity is nearly off-the-charts. Over the last year, company insiders bought shares 79 times and didn’t have a single sell reported, even during the post-January drawdown. I mean, in this market, all I do is hear about insiders dumping shares. MAIA insiders are actually putting more skin in the game with shareholders. We could go on and on about the potential here, but you need to spend some time today and dig into the opportunity before it is too late. Pull up MAIA on your platform right now, and see if it makes sense to you. *Sponsored by Sica Media. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. SECO - Up over 400% in sympathy with TPST Secoo Holding Limited (SECO), through its subsidiaries, operates an integrated online and offline shopping platform in the People's Republic of China, Hong Kong, and internationally. It provides upscale brand products and services, including handbags, watches, clothing, footwear, jewelry and accessories. SECO is up over 400% this morning on no news. TPST closed up over 3900% yesterday and that has set the micro cap sector on fire with stocks like SECO, OPGN up hundreds of percent in the after-hours as small cap euphoria takes hold. $2 was a resistance area in the pre-market and now becomes a potential support level. Above it, targets to the upside are $2.50, $3 and then the pre-market high at $3.79. Beyond that $4, $5 and then $6.90 come into play. Below $2, there is potential support at $1.60, $1.40, $1, $0.75 and a gap fill at $0.3202. OPGN - Up over 700% after receiving $750,000 euros from sale Unyvero A50 systems OpGen (OPGN) is a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Yesterday in the after-hours, [OPGN announced]( that on October 6 it had received $750,000 euros from the sale of Unyvero A50 systems. Given the small cap euphoria started by TPST yesterday, OPGN proceeded to explode over 700% in after-hours trade. $2.50 was resistance in the after-hours and now becomes a potential support level. Above it, targets to the upside are $3, $3.44, $4 and then the pre-market high at $4.34. Beyond that $4.50, $5, $5.50 and $6 come into play. Below $2.50, there is potential support at $2.50, $2, $1.50, $1 and a gap fill at $0.3360. JAGX - Up over 50% in sympathy with OPGN Jaguar Health (JAGX) is a commercial stage pharmaceuticals company that focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. There was no news for the company, but given the other big gappers higher in the small cap space, traders came for JAGX this morning. This is a former biotech runner that is down a lot in recent months due to dilution. $0.70 was a major resistance level in the pre-market and is the first big target for bulls. Above it $0.80, $1, $1.20 and $1.40 come into play. Below $0.70, there is potential support at $0.50, $0.45, $0.40 and a gap fill at $0.24. [Economic Calendar]( To Your Success! P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! PUT THE 1 IN! *This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.  Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull  DISCLAIMER *PAID ADVERTISEMENT. Raging Bull has currently been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on October 12 through October 13, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of MAIA Biotechnology, Inc, increased trading volume, and possibly an increased share price of MAIA Biotechnology, Inc’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in MAIA Biotechnology, Inc, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. FOR COMMERCIAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for commercial and informational purposes only. A portion of our business is engaged in the promotion, marketing, and advertising of companies including public companies. A portion of Raging Bull’s business model is to receive financial compensation to promote public companies, conduct investor relations advertising and marketing, and publicly disseminate information regarding public companies through our websites email, SMS, and push notifications among other methods of communication. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. All material information contained in this advertisement is based on information generally available to the public, including information released to the public or filed by the Company with applicable regulators which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Never invest in any stock featured in this advertisement, on our site or emails unless you can afford to lose your entire investment. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Our advertisements including this advertisement and related emails, reports and alerts may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information in this advertisement, related emails, reports or alerts or on our website or media webpage. This information is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www .sec .gov/edgar/searchedgar/company search TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2023 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States of America